Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial (pages 202–211)Jonathan D. Adachi, Kenneth G. Saag, Pierre D. Delmas, Uri A. Liberman, Ronald D. Emkey, Ego Seeman, Nancy E. Lane, Jean-Marc Kaufman, Patrice E. E. Poubelle, Federico Hawkins, Ricardo Correa-Rotter, Charles-Joel Menkes, Jose A. Rodriguez-Portales, Thomas J. Schnitzer, Joel A. Block, Jeffrey Wing, Harris H. McIlwain, Rene Westhovens, Jacques Brown, Jose A. Melo-Gomes, Barry L. Gruber, Melissa J. Yanover, Maria Odette R. Leite, Kerry G. Siminoski, Michael C. Nevitt, John T. Sharp, Marie-Pierre Malice, Thomas Dumortier, Michelle Czachur, Wendy Carofano and Anastasia Daifotis
Article first published online: 25 JAN 2001 | DOI: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W